Apricus Biosciences Announces Issuance of Key Patent for RayVa for Raynaud's Phenomenon in Israel

Apricus Biosciences, Inc.

announced today that the Israeli Patent Office has allowed and granted the Company a patent entitled, "Topical Compositions for Prostaglandin E1 Delivery." The patent, for the use of Prostaglandin E1 in combination with the Company's proprietary NexACT® technology for Raynaud's Phenomenon covering its drug candidate RayVa™, among other potential product candidates, will provide coverage to May 13, 2019 and expands the protection for Apricus Bio's alprostadil-based products in Israel to eight granted patents.